16 completed, 6 active not recruiting, 2 recruiting. 8 Phase 1, 8 Phase 2, 8 Phase 3.
By phase and status
Follow Povorcitinib: new trials by email Literature Review of Povorcitinib trials Research Report on Povorcitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Povorcitinib, Ruxolitinib - Healthy Participants | Phase 1 | Completed | 24 | 2026-05-18 | 2026-10-09 |
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | 40 | 2026-02-02 | 2026-10-09 |
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Recruiting | 600 | 2025-02-28 | 2026-10-30 |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Povorcitinib, Placebo - Prurigo Nodularis | Phase 3 | Active not recruiting | 349 | 2024-10-10 | 2026-05-28 |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Povorcitinib, Placebo - Prurigo Nodularis | Phase 3 | Active not recruiting | 346 | 2024-10-10 | 2026-04-14 |
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
Povorcitinib - Healthy Participants | Phase 1 | Completed | 18 | 2024-08-12 | 2024-09-26 |
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
Povorcitinib, Placebo, Moxifloxacin - Healthy Participants | Phase 1 | Completed | 128 | 2024-07-12 | 2024-09-25 |
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
Digoxin, Rosuvastatin, Metformin - Healthy Participants | Phase 1 | Completed | 71 | 2024-06-19 | 2025-02-06 |
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
Povorcitinib, Levonorgestrel/Ethinyl estradiol - Healthy Participants | Phase 1 | Completed | 24 | 2024-05-07 | 2024-07-03 |
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Active not recruiting | 617 | 2024-01-30 | 2026-08-25 |
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Povorcitinib, Placebo - NonSegmental Vitiligo | Phase 3 | Active not recruiting | 467 | 2023-11-29 | 2026-08-25 |
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Povorcitinib, Placebo - NonSegmental Vitiligo | Phase 3 | Active not recruiting | 450 | 2023-11-27 | 2026-03-31 |
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | 136 | 2023-07-31 | 2026-03-12 |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
povorcitinib, placebo, ICS-LABA - Moderate to Severe Asthma | Phase 2 | Active not recruiting | 247 | 2023-07-11 | 2026-07-07 |
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Povorcitinib, Placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | 619 | 2023-02-22 | 2026-11-05 |
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
INCB054707 - Renal Insufficiency, Kidney Diseases | Phase 1 | Completed | 43 | 2023-01-12 | 2024-02-13 |
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Povorcitinib, Placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | 608 | 2022-12-19 | 2026-02-10 |
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
INCB054707 - Renal Insufficiency, Kidney Diseases | Phase 1 | Completed | 25 | 2022-12-08 | 2025-08-03 |
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
INCB054707, Placebo - Prurigo Nodularis | Phase 2 | Completed | 146 | 2021-11-04 | 2025-07-11 |
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
INCB054707, Placebo - Healthy Participants | Phase 1 | Completed | 30 | 2021-10-21 | 2022-09-16 |
Showing 20 of 24. Sign in to see all of them.
Conditions studied
Hidradenitis Suppurativa (8) · Hidradenitis (5) · Kidney Diseases (2) · Kidney Failure, Chronic (2) · Renal Insufficiency (2) · Angioedema (1) · Asthma (1) · Chronic Urticaria (1) · Pruritus (1) · Skin Diseases (1) · Urticaria (1)
Sponsors
Incyte Corporation (23) · Incyte Biosciences Japan GK (1)
Countries
United States (22) · Germany (15) · Canada (14) · Poland (12) · Spain (9) · France (8) · Japan (6) · Belgium (5) · Bulgaria (5) · Italy (5) · Netherlands (5) · United Kingdom (5) · Australia (4) · Austria (4) · Czechia (4)
Top investigators
Kathleen Butler, MD (3)
Results publications
PMID 34978076, PMID 42493571, PMID 40518122, PMID 41504465, PMID 42440041, PMID 42570211
NIH funding
2023 (3), 2018 (1)